SCHEMBL6933746

SCHEMBL6933746

CCCCCCCCNc1ccccc1OC

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 9/20 0.76
GBA1 P04062 1/20 0.53
HTR1A P08908 1/20 0.50
ADRA1D P25100 1/20 0.50
ADRA1A P35348 1/20 0.50
ADRA1B P35368 1/20 0.50
GRIN1 Q05586 4/20 0.46
GRIN2A Q12879 4/20 0.46
BCHE P06276 4/20 0.46
ACHE P22303 4/20 0.46
TP53 P04637 1/20 0.46
CHRM4 P08173 1/20 0.46
CYP3A4 P08684 1/20 0.46
CHRM5 P08912 1/20 0.46
CYP2D6 P10635 1/20 0.46
CHRM1 P11229 1/20 0.46
TSHR P16473 1/20 0.46
CHRM3 P20309 1/20 0.46
THPO P40225 1/20 0.46
RECQL P46063 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5287093 1.00 CHRM2 (0.76) CHRM2GBA1HTR1AADRA1DADRA1A
SCHEMBL10490579 1.00 CHRM2 (0.76) CHRM2GBA1HTR1AADRA1DADRA1A
SCHEMBL11634725 1.00 CHRM2 (0.76) CHRM2GBA1HTR1AADRA1DADRA1A
SCHEMBL11496106 0.98 CHRM2 (0.73) CHRM2GBA1HTR1AADRA1DADRA1A
SCHEMBL6173269 0.93 CHRM2 (0.70) CHRM2GBA1HTR1AADRA1DADRA1A
SCHEMBL23467818 0.88 CHRM2 (0.97) CHRM2GRIN1GRIN2ABCHEACHE
SCHEMBL22652639 0.88 CHRM2 (0.97) CHRM2GRIN1GRIN2ABCHEACHE
SCHEMBL16139561 0.88 CHRM2 (0.97) CHRM2GRIN1GRIN2ABCHEACHE
SCHEMBL1644001 0.85 CHRM2 (0.64) CHRM2GBA1HTR1AADRA1DADRA1A
SCHEMBL2397251 0.85 CHRM2 (0.56) CHRM2GBA1HTR1AADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610805-B1 Ligands having a backbone comprised of amine-C-C-X where X is alkoxy or alkylsulfide, for example: 2-(Octylamino)anisole; coordinated with a transition metal and ligand SYMYX TECHNOLOGIES, INC. 2003-08-26 US disclosed
US-6534664-B1 Polymerization catalysts SYMYX TECHNOLOGIES, INC. 2003-03-18 US disclosed
US-6521793-B1 Aromatic secondary amines; polymerization catalysts SYMYX TECHNOLOGIES, INC. 2003-02-18 US disclosed
US-20020072632-A1 Catalyst ligands, catalytic metal complexes and processes using same SYMYX TECHNOLOGIES 2002-06-13 US disclosed
EP-1037872-A1 CATALYST LIGANDS, CATALYTIC METAL COMPLEXES AND PROCESSES USING SAME SYMYX TECHNOLOGIES (US) 2000-09-27 EP disclosed
WO-2000020377-A1 CATALYST LIGANDS, CATALYTIC METAL COMPLEXES AND PROCESSES USING SAME SYMYX TECHNOLOGIES (US) 2000-04-13 WO disclosed
WO-2000008032-A1 CATALYST LIGANDS USEFUL FOR CROSS-COUPLING REACTIONS SYMYX TECHNOLOGIES, INC. (US) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072632-A1 Catalyst ligands, catalytic metal complexes and processes using same CLPX, PICALM, SOD1 CHRM2 4017/4885GBA1 288/4885HTR1A 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.